Ionis CDO Richard Geary retiring Jan 2026; Holly Kordasiewicz to succeed

IONIS PHARMACEUTICALS INC

Richard Geary, EVP & chief development officer, will retire effective January 2026 after 30 years at Ionis.
Holly Kordasiewicz, currently SVP neurology, to become EVP & chief development officer in January 2026.
Geary led 50+ IND submissions and 6 FDA/EU approvals including TRYNGOLZA; will stay as strategic consultant in 2026.
Kordasiewicz has 20 years R&D experience and played key role in QALSODY and IONIS-MAPT Rx Alzheimer's program.

item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Holly Kordasiewicz

executive vice president and chief development officer

IONS · IONIS PHARMACEUTICALS INC

Effective: 2026-01-01
Filed: Jun 12, 2025 23:59 UTC

On June 12, 2025, the Company issued a press release announcing that Holly Kordasiewicz, Ph.D., currently senior vice president, neurology, will succeed Dr. Richard Geary Ph.D. in the role of executive vice president and chief development officer beginning in January 2026.

Departed

Richard Geary

executive vice president and chief development officer

IONS · IONIS PHARMACEUTICALS INC

Effective: 2026-01-01
Successor: Holly Kordasiewicz
Filed: Jun 12, 2025 23:59 UTC

On June 12, 2025, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Richard Geary Ph.D., executive vice president and chief development officer, will retire effective January 2026.

Source: SEC EDGAR

accession 0001140361-25-022267

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.